Prognostic Role of Nucleophosmin in Colorectal Carcinomas

  • Yang, Yu-Feng (Department of Pathology, Dongguan Shilong People's Hospital) ;
  • Zhang, Xi-Ying (Endoscopy Center, Dongguan Shilong People's Hospital) ;
  • Yang, Mei (Department of Gastroenterology, Dongguan Shilong People's Hospital) ;
  • He, Ze-Hua (Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Peng, Ning-Fu (Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Xie, Shu-Rui (Department of Pathology, Dongguan Shilong People's Hospital) ;
  • Xie, Yan-Fang (Department of Pathology, Dongguan Shilong People's Hospital)
  • Published : 2014.03.01


Aim: Recent research suggests that nucleophosmin (NPM) may be a prognostic marker in colorectal carcinomas (CRC). We here tested its use to predict the survival of CRC patients. Methods: We investigated NPM expression by immunohistochemistry in histologically normal to malignant colorectal tissues and evaluated its association with clinicopathological variables. Overall and disease-free survival after tumor removal were calculated by the Kaplan-Meier method, and differences in survival curves were analyzed by the log-rank test. The Cox proportional hazards model was used for multivariate analysis of prognostic factors. Results: NPM expression was found significantly upregulated in CRC compared to adjacent colorectal tissue, villous adenoma, tubular adenoma and normal colorectal mucosa (p<0.05 for all). NPM expression was statistically linked to cancer embolus, lymph node metastasis, differentiation grade, and recurrence of CRC. Overall and disease-free survival of NPM-negative CRC patients tended to be better than those for patients with NPM-positive lesions (log-rank statistic, p<0.05 for all). Multivariate analysis indicated NPM expression as an independent prognostic indicator for CRC patients (p<0.05 ). Conclusion: Our results suggest that NPM expression can predict the survival of CRC patients. Prognosis of CRC is determined by not only many known prognostic factors but also by NPM expression.


  1. Tanaka M, Sasaki H, Kino I, et al (1992). Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res, 52, 3372-7.
  2. Subong EN, Shue MJ, Epstein JI, et al (1999). Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate, 39, 298-304.<298::AID-PROS11>3.0.CO;2-M
  3. Swaminathan V, Kishore AH, Febitha KK, et al (2005). Human histone chaperone nucleophosmin enhances acetylationdependent chromatin transcription. Mol Cell Biol, 25, 7534-45.
  4. Tanaka M, Omura K, Watanabe Y, et al (1994). Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol, 57, 57-64.
  5. Tsui KH, Cheng AJ, Chang PL, et al (2004). Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology, 64, 839-44.
  6. Tsui KH, Juang HH, Lee TH, et al (2008). Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin, 29, 364-70.
  7. Wong JC, Hasan MR, Rahman M, et al (2013). Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. Int J Cancer, 133, 1567-77.
  8. Xu AG, Yu ZJ, Jiang B, et al (2010). Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol, 16, 960-5.
  9. Yun JP, Miao J, Chen GG, et al (2007). Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer, 96, 477-84.
  10. Oshima CT, Iriya K, and Forones NM (2005). Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma, 52, 420-4.
  11. Okuda M (2002). The role of nucleophosmin in centrosome duplication. Oncogene, 21, 6170-4.
  12. Okuda M, Horn HF, Tarapore P, et al (2000). Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell, 103, 127-40.
  13. Okuwaki M, Matsumoto K, Tsujimoto M, et al (2001). Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett, 506, 272-6.
  14. Pianta A, Puppin C, Franzoni A, et al (2010). Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun, 397, 499-504.
  15. Salminen E, Palmu S, Vahlberg T, et al (2005). Increased prolferation activity measured by immunoreactive Ki-67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol, 11, 3245-9.
  16. Sato K, Hayami R, Wu W, et al (2004). Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem, 279, 30919-22.
  17. Savkur RS, Olson MO (1998). Preferential cleavage in preribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res, 26, 4508-15.
  18. Shahab S, Shamsi TS, Ahmed N (2013). Prognostic involvement of nucleophosmin mutations in acute myeloid leaukemia. Asian Pac J Cancer Prev, 14, 5615-20.
  19. Shields LB, Gercel-Taylor C, Yashar CM, et al (1997). Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig, 4, 298-304.
  20. Sportoletti P, Grisendi S, Majid SM, et al (2008). Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 111, 3859-62.
  21. Kurki S, Peltonen K, Laiho M (2004). Nucleophosmin. HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle, 3, 976-9.
  22. Jeong EG, Lee SH, Yoo NJ, et al (2007). Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. APMIS, 115, 341-6.
  23. Karhemo PR, Rivinoja A, Lundin J, et al (2011). An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast Cancer. Am J Pathol, 179, 1004-14.
  24. Kikuta K, Tochigi N, Shimoda T, et al (2009). Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res, 15, 2885-94.
  25. Liu WH, Yung BY (1998). Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate-induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23. Oncogene, 17, 3055-64.
  26. Liu X, Liu Z, Jang SW, et al (2007). Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA, 104, 9679-84.
  27. Liu Y, Zhang F, Zhang XF, et al (2012). Expression of Nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci, 19, 53.
  28. Mukda E, Pintaraks K, Sawangpanich R, et al (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31.
  29. Nakae S, Nakamura T, Ikegawa R, et al (1998). Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol, 69, 28-35.<28::AID-JSO6>3.0.CO;2-M
  30. Nozawa Y, Van Belzen N, Van der Made AC, et al (1996). Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol, 178, 48-52.<48::AID-PATH432>3.0.CO;2-Y
  31. Feuerstein N, Spiegel S, Mond JJ (1998). The nuclear matrix protein, numatrin (B23), is associated with growth factorinduced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody. J Cell Biol, 107, 1629-42.
  32. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, et al (2010). Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. Hum Pathol, 41, 1079-86.
  33. Evans C, Morrison J, Heriot AG, et al (2006). The correlation between colorectal cancer rates of proliferation and apoptosis and systemic levels plus their influence upon survival. Br J Cancer, 94, 1412-9.
  34. Feuerstein N, Chan PK, Mond JJ (1988). Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem, 263, 10608-12.
  35. Fodor IK, Hutchins GG, Espiritu C, et al (2012). Prognostic and predictive significance of proliferation in 867 colorectal cancers. J Clin Pathol, 65, 989-95.
  36. Grisendi S, Mecucci C, Falini B, et al (2006). Nucleophosmin and cancer. Nat Rev Cancer, 6, 493-505.
  37. Guzinska-Ustymowicz K, Pryczynicz A, Kemona A, et al (2009). Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res, 29, 3049-52.
  38. Guzinska-Ustymowicz K, Stepien E, Kemona A (2008). MCM-2, Ki-67 and PCNA Protein Expressions in pT3G2 Colorectal Cancer Indicated Lymph Node Involvement. Anticancer Res, 28, 451-7.
  39. Herrera JE, Savkur R, Olson MO (1995). The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res, 23, 3974-9.
  40. Bertwistle D, Sugimoto M, Sherr CJ (2004). Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol, 24, 985-96.
  41. Choi HJ, Jung IK, Kim SS, et al (1997). Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. Dis Colon Rectum, 40, 51-9.
  42. Cilloni D, Messa F, Rosso V, et al (2008). Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia, 22, 1234-40.
  43. Colombo E, Marine JC, Danovi D, et al (2002). Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol, 4, 529-33.

Cited by

  1. Histone Chaperones: Functions beyond Nucleosome Deposition vol.05, pp.06, 2014,
  2. DEPTOR Expression Negatively Correlates with mTORC1 Activity and Tumor Progression in Colorectal Cancer vol.15, pp.11, 2014,
  3. High SHIP2 Expression Indicates Poor Survival in Colorectal Cancer vol.2014, pp.1875-8630, 2014,
  4. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015,
  5. Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy vol.35, pp.7, 2017,
  6. Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis vol.18, pp.1, 2018,